drugset / Trial / NCT03709628
A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from Crohn's disease.
Timeline
- Start
- 2018-03-07
- Primary completion
- 2019-11-12
- Completion
- 2019-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sibofimloc | Small molecule | 1500 mg | Oral |